Analysts Set Kenvue Inc. (NYSE:KVUE) Price Target at $19.50

Kenvue Inc. (NYSE:KVUE) has been given a consensus rating of “Hold” by the sixteen brokerages that are covering the firm, MarketBeat.com reports. Thirteen research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $19.3333.

KVUE has been the topic of a number of research reports. Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday. UBS Group cut their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Wednesday, April 8th. Canaccord Genuity Group increased their price objective on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Finally, Citigroup dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday.

Hedge Funds Weigh In On Kenvue

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KVUE. Salomon & Ludwin LLC purchased a new position in Kenvue during the third quarter valued at $25,000. NBT Bank N A NY lifted its stake in shares of Kenvue by 180.3% in the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC lifted its stake in shares of Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. increased its position in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in Kenvue during the fourth quarter worth about $26,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.8%

NYSE:KVUE opened at $17.61 on Tuesday. The firm has a market capitalization of $33.80 billion, a P/E ratio of 22.86, a PEG ratio of 3.96 and a beta of 0.61. Kenvue has a 1-year low of $14.02 and a 1-year high of $25.17. The company’s fifty day moving average price is $17.92 and its 200-day moving average price is $17.10. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.05. The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 earnings per share. As a group, equities research analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date was Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is currently 107.79%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.